ジヒドロオロチン酸デヒドロゲナーゼ（DHODH) 阻害剤：対象患者集団・競合情勢・市場予測 (～2034年)

当レポートでは、米国、EU4カ国 (ドイツ、フランス、イタリア、スペイン)、英国、日本におけるジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤の市場を調査し、市場背景、市場動向、既存薬および新興薬の概要、競合情勢、市場シェア、患者数、市場規模の推移・予測、アンメットメディカルニーズ、市場アクセスと償還の動向などをまとめています。

主なハイライト

• DHODH阻害剤はミトコンドリアのピリミジン合成を標的とし、DNA産生を阻害し、急速に分裂する細胞を選択的に抑制します。このメカニズムが、病的な免疫活性化と腫瘍増殖を制御することにより、自己免疫疾患や腫瘍学におけるDHODH阻害剤の治療可能性を支えています。
• 近年、DHODH阻害剤は、多発性硬化症、潰瘍性大腸炎、非ホジキンリンパ腫 (NHL) などの慢性炎症性疾患や自己免疫疾患の治療において有望な治療薬として浮上しています。
• 主要7カ国では、2024年の多発性硬化症の有病者数は米国が最も多いです。
• 2024年には、潰瘍性大腸炎の中等度から重度の症例が、米国では軽度の症例よりも多く報告されました。
• DHODH阻害薬には、レフルノミドとテリフルノミド (AUBAGIO、2023年以降ジェネリック) のみが存在し、自己免疫、がん、ウイルスを適応症とする複数の新規薬剤が臨床開発中です。
• Vidofludimus calcium (Immunic Therapeutics) とJBZ-001 (Jabez Bioscience) は、臨床開発中の有望なDHODH阻害剤です。
• Vidofludimus calciumは多発性硬化症や潰瘍性大腸炎を対象に神経保護作用や抗炎症作用を示し、JBZ-001は進行がんを対象に腫瘍細胞でのピリミジン合成を阻害する第I相段階にあります。

DHODH阻害剤レポート：洞察

• 標的患者集団
• 治療アプローチ
• パイプライン分析
• 市場規模および動向
• 既存および将来の市場機会

DHODH阻害剤レポート：主な強み

• 10年間の予測
• 主要7カ国のカバレッジ
• 主な競合薬
• 薬剤の使用量と主な市場予測の前提条件

DHODH阻害薬レポート：評価

• 現在の治療薬
• アンメットニーズ
• パイプライン製品プロファイル
• 市場の魅力
• 定性分析 (SWOT)

目次

第1章 重要な洞察

第2章 レポートイントロダクション

第3章 ジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤：エグゼクティブサマリー

第4章 主要な出来事

第5章 疫学と市場予測の調査手法

第6章 主要7カ国のジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤市場：概要

• 市場シェア (％) の分布：治療薬別
• 市場シェア (％) の分布：適応症別

第7章 ジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤：背景と概要

• さまざまな適応症における可能性
• 臨床応用

第8章 ジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤：対象患者集団

• 仮定と根拠
• 主な調査結果
• 特定の適応症における総症例数
• 特定の適応症に対する治療適格患者数
• 特定の適応症での実際の治療症例数

第9章 新しいジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤

• 主な競合薬
• Vidofludimus Calcium (IMU-838): Immunic Therapeutics
• JBZ-001: Jabez Bioscience

第10章 ジヒドロオロチン酸デヒドロゲナーゼ (DHODH) 阻害剤：主要7カ国市場の分析

• 主な調査結果
• 市場展望
• コンジョイント分析
• 主要市場予測の前提条件
• 主要7カ国の市場規模：適応症別
• 米国
• EU4カ国・英国
• 日本
  • 市場規模
  • 市場規模：適応症別
  • 市場規模：治療薬別

第11章 SWOT分析

第12章 KOLの見解

第13章 アンメットニーズ

第14章 市場アクセスと償還

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in the 7MM (2020-2034)
• Table 9: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in the 7MM (2020-2034)
• Table 10: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in the United States (2020-2034)
• Table 12: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in the United States (2020-2034)
• Table 13: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in EU4 and the UK (2020-2034)
• Table 14: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in Japan (2020-2034)
• Table 16: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in the 7MM (2020-2034)
• Figure 3: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in the United States (2020-2034)
• Figure 6: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in EU4 and the UK (2020-2034)
• Figure 8: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size in Japan (2020-2034)
• Figure 10: Dihydroorotate Dehydrogenase (DHODH) Inhibitor Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• DHODH inhibitors target mitochondrial pyrimidine synthesis, disrupting DNA production and selectively suppressing rapidly dividing cells. This mechanism underpins their therapeutic potential in autoimmune diseases and oncology by controlling pathological immune activation and tumor growth.
• In recent years, DHODH inhibitors have emerged as a promising therapeutic approach in the treatment of chronic inflammatory and autoimmune conditions such as multiple sclerosis, ulcerative colitis, non-Hodgkin lymphoma (NHL), and others.
• In the 7MM, the United States accounted for the highest number of prevalent cases of Multiple Sclerosis in 2024.
• In 2024, Moderate-to-severe cases of Ulcerative colitis were reported at a higher number than mild cases in the United States.
• The DHODH inhibitor landscape includes only leflunomide and teriflunomide (AUBAGIO, generic since 2023), with several novel agents in clinical development for autoimmune, cancer, and viral indications.
• Vidofludimus calcium (Immunic Therapeutics) and JBZ-001 (Jabez Bioscience) are promising DHODH inhibitors in clinical development.
• Vidofludimus calcium targets multiple sclerosis and ulcerative colitis with neuroprotective and anti-inflammatory effects, while JBZ-001 is in Phase I for advanced cancers, disrupting pyrimidine synthesis in tumor cells.

DelveInsight's "Dihydroorotate Dehydrogenase (DHODH) inhibitor- Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the DHODH inhibitors, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The DHODH inhibitors' market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM DHODH inhibitors' market size from 2020 to 2034. The report also covers current DHODH inhibitors' treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Understanding and Treatment Algorithm

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Overview

DHODH inhibitors are a class of drugs that block the DHODH enzyme, a key player in the de novo synthesis of pyrimidines-molecules essential for DNA and RNA production. This enzyme is located in the mitochondria and supports the rapid proliferation of cells by enabling nucleotide synthesis. By inhibiting DHODH, these drugs limit the availability of pyrimidines, leading to reduced DNA synthesis and cell cycle arrest, particularly affecting rapidly dividing cells.

These inhibitors are used primarily in diseases characterized by excessive immune activation or abnormal cell growth. In autoimmune conditions like rheumatoid arthritis and multiple sclerosis, they suppress the proliferation of overactive immune cells. In oncology, DHODH inhibitors are being studied for their potential to slow the growth of cancer cells, which heavily rely on nucleotide synthesis. Through this mechanism, DHODH inhibitors serve as a targeted approach to control pathological cell activity in various disorders.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Market Overview

In recent years, DHODH inhibitors have emerged as a promising therapeutic approach in the treatment of chronic inflammatory and autoimmune conditions such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and others. Their ability to modulate immune responses by targeting de novo pyrimidine synthesis positions them as potential disease-modifying agents. Clinical data continues to support their utility across these indications, driving interest and investment in this drug class. As development progresses, DHODH inhibitors are increasingly viewed as valuable additions to the immunology pipeline.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Epidemiology

The epidemiology chapter of DHODH inhibitors in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for DHODH inhibitors, total eligible patient pool in selected indications for DHODH inhibitors, and total treated cases in selected indications for DHODH inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• In 7MM, the total prevalent cases of multiple sclerosis in 2024 were approximately 1,287,000 out of which the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 55% of the total prevalent pool.
• In EU4 and the UK, Germany had the highest prevalent pool of multiple sclerosis in 2024, which accounted for approximately 20% of the total 7MM prevalent cases of multiple sclerosis.
• As per DelveInsight analyst's assessments, there were more females affected than males by multiple sclerosis in the United States in 2024.
• In the United States, the highest number of cases of ulcerative colitis was reported in the age group of 18-44 years in 2024.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Drug Chapters

The drug chapter segment of the DHODH inhibitors report encloses a detailed analysis of approved DHODH inhibitors, late-stage (Phase III and Phase II) DHODH inhibitors. It also helps understand the clinical trial details of DHODH inhibitors, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Dihydroorotate Dehydrogenase (DHODH) Inhibitors

The approved landscape of DHODH inhibitors is limited to two agents: leflunomide and its active metabolite teriflunomide. Leflunomide, available in generic form, is primarily used in rheumatoid arthritis. Teriflunomide, marketed as AUBAGIO, is approved for the treatment of multiple sclerosis and became available as a generic in 2023. Beyond these, no other DHODH inhibitors have received regulatory approval. Several novel compounds are in clinical development for autoimmune diseases, cancer, and viral infections, indicating growing interest in this target.

Emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitors

Vidofludimus Calcium (IMU-838): Immunic Therapeutics

Vidofludimus calcium is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis and other chronic inflammatory and autoimmune diseases. The selective immune modulator activates the neuroprotective transcription factor nuclear receptor-related 1 (Nurr1), which is associated with direct neuroprotective properties. Additionally, Vidofludimus calcium is a highly selective inhibitor of the enzyme DHODH, which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of Vidofludimus calcium.

IMU-838, is currently in Phase III and Phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis.

JBZ-001: Jabez Bioscience

JBZ-001, an orally bioavailable small-molecule DHODH inhibitor, was designed to disrupt de novo pyrimidine nucleotide biosynthesis, a critical pathway for cancer cell proliferation. By targeting DHODH, the rate-limiting enzyme in this pathway, JBZ-001 demonstrated the potential to induce cytotoxic effects in tumor cells, offering a promising new approach to cancer treatment. The development of JBZ-001 marks a significant milestone in Jabez Biosciences' "bench-to-bedside" academic collaboration, with the compound receiving FDA approval for a commercial Investigational New Drug (IND) application in 2024. Currently in Phase I of the developmental process for the treatment of patients with advanced solid and hematological malignancies.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Market Outlook

The global DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in targeting metabolic pathways in oncology and Immunology. While only two agents-leflunomide and teriflunomide-are currently approved, a growing clinical pipeline featuring candidates from companies like Immunic Therapeutics, Jabez Bioscience, and others suggests expanded therapeutic potential beyond traditional autoimmune indications.

Key areas of development include multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. As emerging DHODH inhibitors progress through clinical trials, the field is expected to evolve toward more selective and better-tolerated agents. Over the next few years, data from late-stage studies will clarify the clinical value of this class and potentially position DHODH inhibitors as a broader therapeutic platform across immunology and oncology.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging DHODH inhibitors expected to be launched in the market during 2025-2034.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics. The presence of numerous drugs under different stages is expected to generate immense opportunity for DHODH inhibitors' market growth over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for DHODH inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on DHODH inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Washington University and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or DHODH inhibitors' market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on Dihydroorotate Dehydrogenase (DHODH) Inhibitors

• In May 2025, Jabez Biosciences, proudly shared the progress of its Phase I clinical trial for JBZ-001 (HOSU-53), a novel DHODH inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting held April 25-30, 2025, at Chicago. The trial, conducted in collaboration with the Ohio State University Comprehensive Cancer Center, targets adults with advanced solid tumors and NHL.
• In April 2025, Immunic Therapeutics announced that Vidofludimus calcium (IMU-838), a DHODH inhibitor, reduced the risk of disability worsening by 30% in patients with primary progressive multiple sclerosis in the phase II CALLIPER trial.
• In September 2024, Immunic Therapeutics announced the presentation of key data at the 40th Congress of the European Committee for treatment and Research in Multiple Sclerosis (ECTRIMS), highlighting Immunic's lead asset, Vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis.

The abstract list is not exhaustive and will be provided in the final report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the DHODH inhibitors, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the DHODH inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM DHODH inhibitors market.

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Report Insights

• DHODH Inhibitors Targeted Patient Pool
• Therapeutic Approaches
• DHODH Inhibitors Pipeline Analysis
• DHODH Inhibitors Market Size and Trends
• Existing and future Market Opportunities

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Dihydroorotate Dehydrogenase (DHODH) Inhibitors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the total market size of DHODH inhibitors, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for DHODH inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for DHODH inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with DHODH inhibitors? What will be the growth opportunities across the 7MM for the patient population of DHODH inhibitors?
• What are the key factors hampering the growth of the market for DHODH inhibitors?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for DHODH inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the DHODH inhibitors market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Dihydroorotate Dehydrogenase (DHODH) Inhibitors

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Dihydroorotate Dehydrogenase (DHODH) Inhibitors Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2034
• 6.3. Market Share (%) Distribution by Indications in 2025
• 6.4. Market Share (%) Distribution by Indications in 2034

7. Dihydroorotate Dehydrogenase (DHODH) Inhibitors: Background and Overview

• 7.1. Introduction
• 7.2. Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors in Different Indications
• 7.3. Clinical Applications of Dihydroorotate Dehydrogenase (DHODH) Inhibitors

8. Target Patient Pool of Dihydroorotate Dehydrogenase (DHODH) Inhibitors

• 8.1. Assumptions and Rationale
• 8.2. Key Findings
• 8.3. Total Cases of Selected Indication for Dihydroorotate Dehydrogenase (DHODH) Inhibitors in the 7MM
• 8.4. Total Eligible Patient Pool of Selected Indication for Dihydroorotate Dehydrogenase (DHODH) Inhibitors in the 7MM
• 8.5. Total Treatable Cases in Selected Indication for Dihydroorotate Dehydrogenase (DHODH) Inhibitors in the 7MM

9. Emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitors

• 9.1 Key Competitors
• 9.2 Vidofludimus Calcium (IMU-838): Immunic Therapeutics
  • 9.2.1 Product Description
  • 9.2.2 Other Developmental Activities
  • 9.2.3 Clinical Development
  • 9.2.4 Safety and Efficacy
  • 10.2.5. Analyst Views
• 9.3 JBZ-001: Jabez Bioscience
  • 9.3.1 Product Description
  • 9.3.2 Other Developmental Activities
  • 9.3.3 Clinical Development
  • 9.3.4 Safety and Efficacy
  • 9.3.5. Analyst Views

10 Dihydroorotate Dehydrogenase (DHODH) Inhibitors: Seven Major Market Analysis

• 10.1 Key Findings
• 10.2 Market Outlook of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
• 10.3 Conjoint Analysis of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
• 10.4 Key Market Forecast Assumptions of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
  • 10.4.1 Cost Assumptions and Rebates
  • 10.4.2 Pricing Trends
  • 10.4.3 Analogue Assessment
  • 10.4.4 Launch Year and Therapy Uptakes
• 10.5 Total Market Sizes of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Indications in the 7MM
• 10.6 The United States
  • 10.6.1 Total Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors in the United States
  • 10.6.2 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Indication in the United States
  • 10.6.3 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Therapies in the United States
• 10.7 EU4 and the UK
  • 10.7.1 Total Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors in EU4 and the UK
  • 10.7.2 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Indications in EU4 and the UK
  • 10.7.3 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Therapies in EU4 and the UK
• 10.8 Japan
  • 10.8.1 Total Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors in Japan
  • 10.8.2 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Indications in Japan
  • 10.8.3 Market Size of Dihydroorotate Dehydrogenase (DHODH) Inhibitors by Therapies in Japan

11 SWOT Analysis

12 KOL Views

13 Unmet Needs

14 Market Access and Reimbursement

15 Appendix

• 15.1 Bibliography
• 15.2 Report Methodology

16 DelveInsight Capabilities

17 Disclaimer

18 About DelveInsight